8-K: STERIS to Divest Dental Segment to Peak Rock Capital for $787.5 Million

STERIS has agreed to sell its Dental business segment to Peak Rock Capital for $787.5 million in cash, plus a potential $12.5 million earnout.

Summary

• STERIS has entered into an agreement to sell its Dental business segment to HuFriedy Group Holding LLC, an affiliate of Peak Rock Capital LLC.
• The sale price is $787.5 million in cash, subject to adjustments, with a potential additional $12.5 million earnout if the Dental business meets certain revenue targets in fiscal year 2025.
• The agreement includes customary representations, warranties, covenants, and termination rights.
• The deal is expected to close in the first quarter of fiscal year 2025, subject to regulatory approvals and other closing conditions.
• STERIS intends to use the proceeds from the sale primarily to repay debt.
• The Dental segment will be reported as discontinued operations for the fourth quarter and full year of fiscal 2024.
• The Dental segment had revenue of $407 million and operating income of $86 million in the trailing twelve-month period ended December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strategic divestiture, debt reduction, and focus on core markets. However, there are risks associated with the transaction and the loss of a revenue-generating segment.

Positives

• The divestiture allows STERIS to focus on its core markets in healthcare, pharma, and MedTech.
• The sale will provide STERIS with significant cash to reduce debt.
• The reduction in debt is expected to improve earnings per share by approximately $0.35 on a full year run rate basis.
• The Dental segment will be reported as discontinued operations, which may improve the appearance of the remaining business's financial performance.

Negatives

• STERIS is losing a business segment that generated $407 million in revenue and $86 million in operating income.
• The transaction is subject to regulatory approvals and other closing conditions, which could delay or prevent the sale.
• There is a risk that the earnout payment may not be achieved if the Dental business does not meet the required revenue targets.

Risks

• The transaction may not close on the expected terms or within the anticipated timeframe.
• Regulatory approvals may be delayed or impose adverse conditions.
• STERIS may not realize the expected benefits of the transaction, including the earnout payment.
• There are risks related to the integration of acquired businesses and potential liabilities.
• Changes in tax laws or interpretations could increase STERIS's tax liabilities.
• Market demand for new technologies may not develop as anticipated.
• There are risks associated with international unrest, economic downturns, and currency fluctuations.
• Supply chain issues could delay the manufacture or shipment of products.
• The level of STERIS's indebtedness could limit financial flexibility.
• Changes in credit availability and pricing could affect STERIS's customers and suppliers.

Future Outlook

STERIS will provide an outlook for fiscal 2025 reflecting the divestiture when fourth quarter fiscal 2024 results are issued. The company expects a reduction in interest expense of approximately $0.35 per diluted share on a full year run rate basis.

Management Comments

• Dan Carestio, President and Chief Executive Officer of STERIS, stated that they have been impressed with the strength of the Dental team and their adoption of lean philosophies.
• Dan Carestio also mentioned that the divestiture will allow STERIS to focus on customers within their core markets.

Industry Context

The divestiture of the Dental segment suggests a strategic shift for STERIS, focusing on its core healthcare, pharma, and MedTech markets. This move is consistent with companies streamlining operations to concentrate on areas with the highest growth potential and profitability. The sale to a private equity firm like Peak Rock Capital is a common transaction in the current market environment.

Comparison to Industry Standards

• The divestiture of a non-core business segment is a common strategy for companies looking to streamline operations and focus on core competencies, similar to actions taken by other large medical device and healthcare companies.
• The valuation of the Dental segment at approximately 1.9x trailing twelve-month revenue is within the typical range for similar transactions in the healthcare industry.
• The use of proceeds to pay down debt is a common practice to improve financial health and reduce interest expenses, which is a strategy employed by many companies in the current economic environment.
• The earnout structure is a common mechanism in M&A deals to align the interests of the buyer and seller and ensure the continued performance of the divested business.

Stakeholder Impact

• Shareholders may benefit from the debt reduction and focus on core markets.
• Employees of the Dental segment will transition to new ownership under Peak Rock Capital.
• Customers of the Dental segment will experience a change in ownership.
• Creditors may benefit from the debt repayment by STERIS.

Next Steps

• STERIS will seek regulatory approvals for the transaction.
• The transaction is expected to close in the first quarter of fiscal year 2025.
• STERIS will provide an updated outlook for fiscal year 2025 when fourth quarter fiscal 2024 results are released.

Key Dates

Keywords

divestiture, dental segment, acquisition, Peak Rock Capital, STERIS, debt repayment, healthcare, MedTech, pharma, equity sale